Form 8-K FATE THERAPEUTICS INC For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Fate Therapeutics (FATE) Tops Q3 EPS by 6c
November 3, 2015 4:28 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
... More